Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected pulmonary metastases from colorectal cancer

Turan, Nedim; Benekli, Mustafa; Dane, Faysal; Unal, Olcun; Kara, Hasan; Koca, Dogan; Balvan, Ozlem; Eren, Tulay; Tastekin, Didem; Helvaci, Kaan; Berk, Veli; Demirci, Umut; Ozturk, Selcuk; Dogan, Erkan; Cetin, Bulent; KÜÇÜKÖNER, MEHMET; Tonyali, Onder; Tufan, Gulnihal; Oztop, Ilhan; Gumus, Mahmut; Coskun, UĞUR; ÜNER, AYTUĞ; ÖZET, AHMET; Buyukberber, Suleyman

doi:10.1111/1759-7714.12107

Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected pulmonary metastases from colorectal cancer

Atıf İçin Kopyala

Turan N., Benekli M., Dane F., Unal O. U., Kara H. V., Koca D., ...Daha Fazla

THORACIC CANCER, cilt.5, sa.5, ss.398-404, 2014 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 5 Sayı: 5
Basım Tarihi: 2014
Doi Numarası: 10.1111/1759-7714.12107
Dergi Adı: THORACIC CANCER
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.398-404
Anahtar Kelimeler: Adjuvant chemotherapy, bevacizumab, colorectal cancer, pulmonary metastasectomy, III COLON-CANCER, RANDOMIZED CONTROLLED-TRIAL, LUNG METASTASECTOMY, PHASE-III, PROGNOSTIC-FACTORS, K-RAS, BOLUS FLUOROURACIL, MUTATION STATUS, STAGE-II, OXALIPLATIN
Gazi Üniversitesi Adresli: Evet

Özet

Introduction: We investigated the impact of modern chemotherapy regimens and bevacizumab following pulmonary metastasectomy (PM) from metastatic colorectal cancer (CRC).